Follow
Joshua Pankrac, PhD
Joshua Pankrac, PhD
Founder & CEO, Omni Biologics
No verified email
Title
Cited by
Cited by
Year
Addressing an HIV cure in LMIC
SD Ismail, J Pankrac, E Ndashimye, JL Prodger, MR Abrahams, ...
Retrovirology 18 (1), 21, 2021
352021
Eradication of HIV-1 latent reservoirs through therapeutic vaccination
J Pankrac, K Klein, JFS Mann
AIDS research and therapy 14, 1-4, 2017
282017
A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system
J Pankrac, K Klein, PF McKay, DFL King, K Bain, J Knapp, T Biru, ...
npj Vaccines 3 (1), 2, 2018
222018
A targeted reactivation of latent HIV-1 using an activator vector in patient samples from acute infection
JFS Mann, J Pankrac, K Klein, PF McKay, DFL King, R Gibson, ...
EBioMedicine 59, 2020
122020
Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope
AN Ratcliff, CM Venner, AS Olabode, J Knapp, J Pankrac, I Derecichei, ...
Journal of Virology 96 (14), e01851-21, 2022
22022
Blocking T‐cell egress with FTY720 extends DNA vaccine expression but reduces immunogenicity
JFS Mann, PF McKay, K Klein, J Pankrac, JS Tregoning, RJ Shattock
Immunology 165 (3), 301-311, 2022
12022
Effective and targeted latency reversal in CD4+ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection
MH Ngo, J Pankrac, RCY Ho, E Ndashimye, R Pawa, R Ceccacci, T Biru, ...
Emerging Microbes & Infections 13 (1), 2327371, 2024
2024
PP 3.15–00207 A polyvalent HIV-1 virus-like particle formulation drives the majority of the infectious HIV-1 reservoir out of latency within CD4+ T cells of individuals …
E Arts, J Pankrac, R Ho, MH Ngo, J Prodger, A Redd, T Quinn, C Kovacs, ...
2022
Development and Evaluation of a Heterogenous Virus-Like Particle (VLP) Formulation to Achieve HIV-1 Latency Reversal and Cure
JP Pankrac
The University of Western Ontario (Canada), 2020
2020
Development of a Latency Reversing Activator Vaccine (ACT-VEC) Platform as a Curative Approach for SIV
J Mann, R Veazey, J Pankrac, K Klein, E Arts
AIDS RESEARCH AND HUMAN RETROVIRUSES 32, 402-402, 2016
2016
The system can't perform the operation now. Try again later.
Articles 1–10